Valvular heart disease associated with taking low-dose pergolide for restless legs syndrome

European Journal of Echocardiography

Volumn 9, Issue 6, 2008, Pages 828-830

  Worthington, Angela ^a   Thomas, Liza ^b,c  

^a WESTMEAD HOSPITAL   (Australia)

^b LIVERPOOL HOSPITAL   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Dopamine agonists; Pergolide; Restless legs syndrome; Valvular heart disease

Indexed keywords

CLONAZEPAM; DIGOXIN; DOSULEPIN; FUROSEMIDE; PERGOLIDE; PHENYTOIN; WARFARIN;

ADULT; ANAMNESIS; ANGIOCARDIOGRAPHY; AORTA VALVE REGURGITATION; AORTA VALVE REPLACEMENT; ARTICLE; CASE REPORT; CLINICAL FEATURE; EVENING DOSAGE; FEMALE; HEART FAILURE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LOW DRUG DOSE; MITRAL VALVE REGURGITATION; MITRAL VALVE REPLACEMENT; PRIORITY JOURNAL; RESTLESS LEGS SYNDROME; SIDE EFFECT; TRANSTHORACIC ECHOCARDIOGRAPHY;

AORTIC VALVE INSUFFICIENCY; DOPAMINE AGONISTS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEART VALVE PROSTHESIS IMPLANTATION; HUMANS; MIDDLE AGED; MITRAL VALVE INSUFFICIENCY; PERGOLIDE; RESTLESS LEGS SYNDROME; TREATMENT OUTCOME;

EID: 54949134146     PISSN: 15252167     EISSN: 15322114     Source Type: Journal    
DOI: 10.1093/ejechocard/jen191     Document Type: Article

References (11)

1. FDA warning. 29 March 2007.
2. Jick H, Vasilakis C, Weinrauch LA et al. A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation. N Engl J Med 1998;339:719.
3. Hendrikx M, Van Dorpe J, Flameng W, Daenen W. Aortic and mitral valve disease induced by ergotamine therapy for migraine: a case report review of the literature. J Heart Valve Dis 1996;5:235.
4. Bana DS, MacNeal PS, LeCompte PM et al. Cardiac murmurs and endocardial fibrosis associated with methysergide therapy. Am Heart J 1974;88:640.
5. Pritchett AM, Morrison JF, Edwards WD et al. Valvular heart disease in patients taking pergolide. Mayo Clin Proc 2002;77:1280.
6. Waller EA, Kaplan J, Heckman MG, Valvular heart disease in patients taking pergolide. Mayo Clin Proc 2005;80:1016.
7. Rothman RB, Baumann MH, Savage JE et al. Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation 2000;102:2836.
8. Van Camp G, Flamez A, Cosyns B et al. Heart valvular disease in patients with Parkinson's disease treated with high-dose pergolide. Neurology 2003:61: 859-861.
9. Van Camp G, Flamez A, Cosyns B et al. Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease. Lancet 2004;363:1179-83.
10. Mast ST, Jollis JG, Ryan T et al. The progression of fenfluramine-associated valvular heart disease assessed by echocardiography. Ann Intern Med 2001;134:261.
11. Zanettini R, Antonini A, Gatto G et al. Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med 2007;356:39.